home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences

Search

 
  IBC's Application of "Appropriate" cGMPs in Biopharmaceutical Drug Development  
  January 31, 2002

Others

 
     
  IBC USA Conferences, Inc., Las Vegas, NV, Princeton, NJ, San Francisco, CA
May 6-7, 2002, June 20-21, 2002, July 15-16, 2002


This two day course will cover the basic requirements for taking a “New Chemical Entity “ (NCE) from early stages of drug development to pivotal clinical trials. This will cover the basic requirements of GLPs, GMPs and GCPs. The instructor will discuss by way of examples how to interpret and apply the cGMP regulations (21 CFR 210, 211 and 600) for the manufacture and control of pre-clinical and clinical supplies. The application of these regulations in an “appropriate” manner is crucial to drug development. This course will also discuss the phases of clinical studies and how to use the “graded” approach to the manufacture of clinical supplies as a NCE progresses through drug development.
 
 
Organized by: IBC USA Conferences, Inc.
Invited Speakers: K.A. Ajit-Simh, Principal, Shiba Associates
 
Deadline for Abstracts: -
 
Registration: Five Easy Ways to Register!
Phone (508) 616-5550
Fax (508) 616-5522
E-mail reg@ibcusa.com
Online www.LifeSciencesInfo.com/2747
Mail
IBC USA Conferences, Inc.
One Research Drive, Suite 400A
Westborough, MA 01581-5195
E-mail: reg@ibcusa.com
 
  Posted by:   James G. Prudhomme  
Host: 208.252.12.3
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2002 HUM-MOLGEN. All rights reserved. Liability and Copyright.